BerGenBio

Sustainability Report and Carbon Intensity Rankings

Is BerGenBio doing their part?

Their DitchCarbon score is 47

BerGenBio has a DitchCarbon Score of 47 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, which suggests there is significant room for improvement in reducing emissions. A higher score would demonstrate a stronger commitment to lowering carbon intensity and enhancing sustainability efforts.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

BerGenBio is a company in the research and development sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Medium

High

Very high

BerGenBio, located in Norway, benefits from the country’s very low carbon intensity, indicating a greener operational environment. This suggests that the company’s sustainability efforts are supported by Norway’s commitment to low carbon emissions.

Unlock 30+ emissions intelligence data points

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

Unlock 30+ emissions data points on BerGenBio

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

4.36%

...this company is doing 4.36% worse in emissions than the industry average.

BerGenBio, founded in 2008 and based in Bergen, operates within the research and development sector of the biopharmaceutical industry. The company specializes in the development of selective AXL kinase inhibitors, aiming to combat aggressive cancers by targeting mechanisms responsible for cancer spread and drug resistance. As a leader in understanding AXL kinase’s role in cancer, BerGenBio seeks to provide new therapeutic options for patients facing this disease.

Compare BerGenBio with other companies in the same industry –>

emission intelligence's platform recommendations for BerGenBio

BerGenBio should foster the adoption of remote collaboration tools such as video conferencing to minimize business travel, thereby potentially reducing their scope 3 emissions by 0.5%.

Bad news, BerGenBio hasn't committed to SBTi goals yet

BerGenBio has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company has not defined or announced clear goals to reduce greenhouse gas emissions in line with climate science.

Not participating

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.

Other company reports in this industry

Looking for a specific company?

Search our company directory or contact us for custom data requests.

BerGenBio

Sustainability Report and Carbon Intensity Rankings

Is BerGenBio doing their part?

Their DitchCarbon score is 47

Industry emissions intensity

Very low

Low

Medium

High

Very high

Location emissions intensity

Very low

Low

Medium

High

Very high

Unlock 30+ emissions intelligence data points

Unlock 30+ emissions data points on BerGenBio

...this company is doing 4.36% worse in emissions than the industry average.

emission intelligence's platform recommendations for BerGenBio

Bad news, BerGenBio hasn't committed to SBTi goals yet

Claim this profile

Our methodology

Other company reports in this industry

Looking for a specific company?

Quicklinks

Resources

Get in touch